{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:47:57Z","timestamp":1763142477290,"version":"3.44.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,27]]},"DOI":"10.7759\/cureus.93341","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:07Z","timestamp":1758982087000},"source":"Crossref","is-referenced-by-count":1,"title":["Checkpoint Inhibitor-Associated Myasthenia\u2013Myositis Overlap With Neuromuscular Respiratory Failure After Dual PD-L1 Plus CTLA-4 Checkpoint Blockade for Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"Adam M","family":"Bowen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dania","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramalakshmi","family":"Thulluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miller","family":"Lantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfarooq","family":"Alshaikhli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa GK","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, et al.. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022, 1:2100070. 10.1056\/EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro B","year":"2024","unstructured":"Sangro B, Chan SL, Kelley RK, et al.. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024, 35:448-57. 10.1016\/j.annonc.2024.02.005","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe DN","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, et al.. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024, 14:1794. 10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02858-7","article-title":"Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report","volume":"15","author":"Cham J","year":"2021","unstructured":"Cham J, Ng D, Nicholson L. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. J Med Case Rep. 2021, 15:278. 10.1186\/s13256-021-02858-7","journal-title":"J Med Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3028-23","article-title":"A rare case of overlapping durvalumab-induced myositis, takotsubo-like morphological changes caused by myocarditis, and myasthenia gravis","volume":"63","author":"Saito S","year":"2024","unstructured":"Saito S, Hontsu S, Hiraoka J, et al.. A rare case of overlapping durvalumab-induced myositis, takotsubo-like morphological changes caused by myocarditis, and myasthenia gravis. Intern Med. 2024, 63:3209-15. 10.2169\/internalmedicine.3028-23","journal-title":"Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin Y","year":"2024","unstructured":"Qin Y, Chen S, Gui Q, et al.. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024, 15:1372861. 10.3389\/fneur.2024.1372861","journal-title":"Front Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen LS","year":"2022","unstructured":"Nguyen LS, Bretagne M, Arrondeau J, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022, 10:004699. 10.1136\/jitc-2022-004699","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/412600-checkpoint-inhibitor-associated-myasthenia-myositis-overlap-with-neuromuscular-respiratory-failure-after-dual-pd-l1-plus-ctla-4-checkpoint-blockade-for-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:07Z","timestamp":1758982087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/412600-checkpoint-inhibitor-associated-myasthenia-myositis-overlap-with-neuromuscular-respiratory-failure-after-dual-pd-l1-plus-ctla-4-checkpoint-blockade-for-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.93341","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,27]]}}}